← Eichor
Study identifier: NCT06207981 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Phase III Study Evaluating Induction Chemotherapy Followed by Chemoradiotherapy Compared to Standard Chemoradiotherapy for Locally Advanced SCCA

Condition: Anal Cancer  ·  Sponsor: Federation Francophone de Cancerologie Digestive

PhasePhase 3
Planned participants310
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Squamous cell carcinoma of the anus is still a rare disease but its incidence increases mostly due to its association with human papillomavirus (HPV). When localized, the standard treatment combines radiotherapy and chemotherapy with 5FU and mitomycin-C. Chemoradiotherapy (CRT) achieves a good outcome for early stage tumors (T1-T2 tumors without nodal involvement), but more advanced tumors (T3-T4 or N1) are associated with a dismal prognosis. About 35 % of such patients relapse within two years after the end of treatment Recently, for metastatic or recurrent tumors after chemoradiotherapy, a chemotherapy combining docetaxel, cisplatin and 5FU (modified DCF protocol) has given very good results with a median overall survival of 39.2 months in 2 French trials (Epitopes HPV01 and 02). Our idea is to propose a new strategy , associating this chemotherapy (mDCF) followed by chemoradiotherapy to improve efficacy of the treatment for patients with locally advanced anal cancers. To this end, The principal investigator propose a national, multicenter, randomized phase 3 clinical trial to compare induction chemotherapy with mDCF followed by chemoradiotherapy versus standard chemoradiotherapy for locally advanced anal canal cancer. the efficacy of the treatment will be evaluated by comparing disease-related event-free survival at 2 years according to the type of treatment. Other endpoints will also be evaluated such as overall survival and colostomy-free survival, treatment tolerabilit…

This description comes directly from the study's public registry record.

Talk to the study team

Veronique Vendrely, Md-pHD  ·  +33 380393483  ·  prodige85.kanalrad@ffcd.fr

Jérémie BEZ, MS  ·  +33 380393483  ·  prodige85.kanalrad@ffcd.fr

Always discuss trial participation with your own doctor first.

Locations (114)

AGEN-CromgAgen, FranceNot Yet Recruiting
Clinique CalabetAgen, FranceNot Yet Recruiting
AIX EN PROVENCE CH Pays d'AixAix-en-Provence, FranceNot Yet Recruiting
Amiens - Clinique de L'EuropeAmiens, FranceNot Yet Recruiting
ANTONY Hôpital PrivéAntony, FranceNot Yet Recruiting
Argenteuil - ChArgenteuil, FranceRecruiting
ARRAS Les BonnettesArras, FranceNot Yet Recruiting
ARRAS Marie CurieArras, FranceNot Yet Recruiting
AURILLAC-Henri MondorAurillac, FranceNot Yet Recruiting
Centre Medico ChirurgicalAurillac, FranceNot Yet Recruiting
AUXERRE CH GHT UnyonAuxerre, FranceRecruiting
Avignon IcapAvignon, FranceRecruiting

+ 102 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06207981